



Vera Therapeutics Scheduled to Present at November Investor Conferences

October 30, 2023

BRISBANE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present and participate in one-on-one meetings at the following investor conferences, as detailed below:

Guggenheim 5th Annual Inflammation, Neurology, & Immunology Conference

Format: Fireside Chat

Date and Time: Monday, November 6, 2023, 9:50 – 10:20 AM EST

Webcast: <https://guggenheim.metameetings.net>

6th Annual Evercore ISI HealthCONx Conference

Format: Fireside Chat

Date and Time: Thursday, November 30, 2023, 10:50 – 11:10 AM EST

Webcast: <https://wsw.com/webcast/evercore39/vera>

A replay of the presentations will be available for 30 days and can be accessed by visiting the "[Investor Calendar](#)" section of the Vera Therapeutics website.

About Vera Therapeutics

Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera's mission is to advance treatments that target the source of immunologic diseases in order to change the standard of care for patients. Vera's lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B Lymphocyte Stimulator (BLyS) and A Proliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger's disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. For more information, please visit www.veratx.com.

[For more information, please contact:](#)

Investor Contact:

Joyce Allaire

LifeSci Advisors

212-915-2569

jallaire@lifesciadvisors.com

Media Contact:

Minyan Weiss

Uncapped Communications, Inc.

Minyan.Weiss@uncappedcommunications.com